{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T08:39:05.607512+00:00","company":{"ticker":"APGE","cik":1974640,"company_name":"Apogee Therapeutics, Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"99bdfa4a2d3e6efff305e554f02893a42a5379c4","cik":1974640,"ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-05-11T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-05-11","result_type":"reported_results","revenue_text":null},"claim":"Apogee Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.","evidence_excerpt":"On May 11, 2026, Apogee Therapeutics, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter ended March 31, 2026 (the “Earnings Press Release”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-215683","anchor_url":"https://secwatch.observer/filing/0001193125-26-215683#claim-99bdfa4a2d3e6efff305e554f02893a42a5379c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1974640/000119312526215683/0001193125-26-215683-index.htm"},{"fact_type":"material_agreement","fact_key":"7a8c5d897ffc53a2d4e5777657601a62f126daa9","cik":1974640,"ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-03-25T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC","effective_date":"2026-03-24","item_codes_triggered":["1.01"],"value_text":"$70.00 per share"},"claim":"Apogee Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC valued at $70.00 per share (effective 2026-03-24).","evidence_excerpt":"On March 24, 2026, Apogee Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the Underwriters named therein (the “Underwriters”), to issue and sell 5,000,000 shares of the Company’s common stock at a public offering price of $70.00 per share (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-034579","anchor_url":"https://secwatch.observer/filing/0001104659-26-034579#claim-7a8c5d897ffc53a2d4e5777657601a62f126daa9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926034579/0001104659-26-034579-index.htm"},{"fact_type":"executive_change","fact_key":"bcf25cecb9","cik":1974640,"ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-05-28T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-28","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Lisa L. Bollinger was elected as Class II director at Apogee Therapeutics, Inc..","evidence_excerpt":"the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) elected Lisa L. Bollinger, M.D. to serve as a Class II director of the Company","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-065322","anchor_url":"https://secwatch.observer/filing/0001104659-24-065322#claim-bcf25cecb9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924065322/0001104659-24-065322-index.htm"},{"fact_type":"earnings_release","fact_key":"d6590d7a00c985dfedf51185264a3dbf6376b020","cik":1974640,"ticker":"APGE","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"Apogee Therapeutics, Inc. reported financial results for first quarter 2024.","evidence_excerpt":"On May 13, 2024, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-060195","anchor_url":"https://secwatch.observer/filing/0001104659-24-060195#claim-d6590d7a00c985dfedf51185264a3dbf6376b020","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924060195/0001104659-24-060195-index.htm"}]}